Skip to content

About us

What we do

We want to cure cancer that until now could not be cured!

18 million new cancer cases occur annually, and about 9 million deaths attributable to cancer are recorded each year, illustrating the magnitude of the impact of malignant tumors on human health.

Our cell therapy product pTTL – personalised Tumour Trained Lymphocytes – provides a unique immunotherapy with the aim to treat solid cancer without side effects. Preparations for the first clinical study in solid cancer is currently underway.

In pTTL our proprietary technologies, PIOR™ software and EpiTCer® are applied for identifying the most optimal neoantigens to target and to activate and multiply T-lymphocytes against the identified neoantigens with the purpose of eradicating the cancer.

EpiTCer® is a powerful technology that can also be utilised in other application areas such as vaccination and T-cell diagnostics.

Who we are

NEOGAP Therapeutics is a privately held biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund and is located at Centre for Molecular Medicine at Karolinska Institutet, Stockholm, Sweden.

We are a multidisciplinary team with highly skilled and motivated individuals, bringing together an extensive experience and track record from academia and the pharmaceutical industry.

Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system.

Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy expected to act without side effects.

Management Team

Hans
Grönlund

CSO

PhD,  Assoc Prof  Karolinska Institutet.

HansGronlund

Guro
Gafvelin

CTO

PhD, Assoc Prof Karolinska Institutet.

GuroGafvelin

Samuel
Svensson

CEO

PhD, Prof Pharmacology.

SamuelSvensson

Andrea
Salmén

Project Leader

MSc Engineering Biology.

AndreaSalmen_dator

Ola
Winqvist

CMO

MD, PhD, Prof Clinical immunology. 

OlaWinqvist

Board of Directors

Chairman of the board

MD, PhD, Assoc Prof

Specialist Internal medicine.
Karolinska Institutet.

PhD, Assoc Prof

Karolinska Institutet, Pharmacia-Upjohn, Viscogel, Athera Biotech., Medirista Biotech, Meditec.
PhD, Assoc Prof

Karolinska Institutet, Viscogel, Meditec.

MD, PhD

Celgene, Pfizer, AstraZeneca, University of Bergen, UT Southwestern Medical Center,  Karolinska Institutet.

Acting CFO

Viscogel AB, Moberg Pharma AB (publ.), Oriflame Cosmetics.

IBM, Bluegarden, Medi-Tec, Isartes.

Scientific Advisory Board

MD, PhD  

Professor of Oncology, Karolinska Institutet, Senior Consultant, Oncology Clinic, Karolinska Hospital. 

MD, PhD  

Professor of Experimental Oncology, Karolinska Institutet, Senior Consultant, Oncology Clinic, Karolinska Hospital.

PhD  

RegSmart Life Sciences, Swedish MPA, Sofus, Orexo, AstraZeneca

MD, PhD 

Professor of Neurology, Karolinska Institutet. Former member of the Nobel Assembly.